Navigation Links
Haemonetics Reports Third Quarter of Fiscal 11
Date:1/31/2011

n $90 million.

Brian Concannon, Haemonetics' President and CEO, said, "I continue to be encouraged by the positive momentum in our business and the excellent operating discipline which has driven strong earnings performance, both in the quarter and year to date. The return to growth in our commercial plasma business is also very encouraging and the sequential growth rates tell the story of a real recovery in demand for our plasma products, which we expect to continue in fiscal 12."

STRATEGIC AND SEGMENT GROWTH HIGHLIGHTSHaemonetics continues to make progress expanding its business.  The Company reported the following highlights:

  • In the quarter, average weekly plasma shipments were up 17% from the low point in the recent plasma downturn which occurred in Q4 of fiscal 10.
  • 47 additional IMPACT™ customers in Q3 fiscal 11 bringing the total number of IMPACT customers to 165, driving accelerated revenue growth in key product lines evidenced by a 21% Q3 growth rate for TEG®  Thrombelastograph® Hemostasis Analyzer disposables.
  • Platelets grew 3% in the quarter and 5% year to date, reflecting strong double digit growth in the Company's emerging markets business units.
  • In the quarter, equipment revenue grew 16% year over year.  Equipment sales are a leading indicator of disposables revenue.
  • The Global Med acquisition integration is proceeding well against its planned schedule and operating income targets.

  • Mr. Concannon added, "We've made great progress in adding IMPACT accounts and these accounts are generating significantly higher growth rates as they implement a differentiated approach to blood management.  I remain confident in our ability to achieve our full year target of 175 IMPACT accounts by fiscal year end."

    As noted, Haemonetics' third quarter fiscal 11 reported revenues were $176.8 million, up 7%.  Reported revenues break down as follows:

    P
    '/>"/>

    SOURCE Haemonetics Corporation
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

    Related biology technology :

    1. Haemonetics Receives Favorable Ruling in Patent Lawsuit against Competitive Technology
    2. Neogen Reports 33% Increase in Net Income
    3. Cardium Reports Excellagen Matrix Clinical Study Results Accepted for Publication by Peer-Reviewed Journal, and Updates Product Plans
    4. New Topical Patent Research Reports Recently Published at MarketPublishers.com
    5. YM BioSciences Reports Positive Interim Data Including Substantial Anemia Response from Phase I/II Trial of JAK1/JaK2 Inhibitor CYT387
    6. Oncothyreon Reports Positive Data from Phase 1 Clinical Trial of PI3-Kinase Inhibitor PX-866 in Patients with Relapsed or Refractory Solid Tumors
    7. GeneLink Reports Third Quarter Results
    8. Imagenetix, Inc. Reports Second Quarter 2011 Results
    9. Transgenomic Reports Third Quarter Financial Results
    10. Tiens Biotech Group (USA) Reports Third Quarter and Nine-Month Results
    11. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2011 Results; Teleconference and Webcast to be held on November 16, 2010
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/11/2014)... 2014 , Not for release, publication ... from any jurisdiction where to do so would constitute a ... Shire plc ("Shire" or the "Company") (LSE: SHP, NASDAQ: ... confirms it has held a meeting with representatives of AbbVie. ... the prior agreement or approval of AbbVie. A ...
    (Date:7/11/2014)... 2014 /CNW/ - Sunovion Pharmaceuticals Canada Inc. (Sunovion) today ... acetate) for use as a once-daily adjunctive therapy for ... who are not satisfactorily controlled with conventional therapy.  APTIOM ... under 18 years of age. Epilepsy ... according to Epilepsy Canada, it affects 0.6% of the ...
    (Date:7/10/2014)... (PRWEB) July 10, 2014 Product ... in very low abundance and are often “lost ... and time-consuming. , Join presenters Dr. Rowel Tobias, ... Dr. John Anders, Head of Quality at Nanotherapeutics, ... approach that can speed detection and quantitation while ...
    (Date:7/10/2014)... CA (PRWEB) July 10, 2014 Unraveling ... closer together. The Archer Family purchased a ... within DNA, but ended up with a lifetime of ... contained within the family members’ DNA genuinely brought the ... decided to search deeper into genetic history and prior ...
    Breaking Biology Technology:Shire plc - Statement re: Media Speculation 2Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 2Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 3Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 4Novel Ms Techniques Speed Detection of Biopharmaceutical Product and Process Impurities, New Webinar Hosted by Xtalks 2Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 2Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 3Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 4Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 5
    ... N.J., July 10 Senesco Technologies , Inc. ... announced that, on July 9, 2009, the Company entered into a ... sale of (i) up to 1,111,111 shares of its common stock ... to purchase an aggregate of up to 1,000,000 shares of common ...
    ... of Energy,s Lawrence Berkeley National Laboratory and the University ... fabricate efficient solar cells from low-cost and flexible materials. ... of nanoscale pillars, each a single crystal, with dimensions ... take advantage of abundant solar energy we have to ...
    ... July 9 PharmAthene, Inc. (NYSE Amex: ... biological and chemical threats, today announced that the U.S. ... of the Company,s proposed development plan for SparVax(TM), PharmAthene,s ... , In response to amendments to the request ...
    Cached Biology Technology:Senesco Technologies Enters Into Agreement For Up To $1.0 Million In Financing 2Senesco Technologies Enters Into Agreement For Up To $1.0 Million In Financing 3Senesco Technologies Enters Into Agreement For Up To $1.0 Million In Financing 4Nanopillars promise cheap, efficient, flexible solar cells 2Nanopillars promise cheap, efficient, flexible solar cells 3PharmAthene's 2nd Generation rPA Anthrax Vaccine, SparVax(TM), Completes FDA Regulatory Strategy Review 2PharmAthene's 2nd Generation rPA Anthrax Vaccine, SparVax(TM), Completes FDA Regulatory Strategy Review 3PharmAthene's 2nd Generation rPA Anthrax Vaccine, SparVax(TM), Completes FDA Regulatory Strategy Review 4
    (Date:7/11/2014)... of Standards and Technology (NIST) need a special ... often prove that necessity is truly the mother ... M. Lorna De Leoz and Stephen Stein, NIST ... Glycomics is the study of the abundant, often-branched ... proteins and lipids and influence cellular processes, including ...
    (Date:7/11/2014)... 3, 2014, Shenzhen, China Researchers from Salk Institute ... the first time evaluated the safety and reliability ... successfully developed a new method, TALEN-HDAdV, which could ... stem cell (hiPSC). This study published online in ... theoretical foundation for stem cell-based gene therapy. , ...
    (Date:7/11/2014)... the Max Planck Institute for Medical Research in Heidelberg, ... photosynthesis, the process by which the Earth first gained ... which is therefore crucial for all higher forms of ... first direct visualization of a crucial event in the ... protein complex, photosystem II, splits water into hydrogen and ...
    Breaking Biology News(10 mins):A new genome editing method brings the possibility of gene therapies closer to reality 2A first direct glimpse of photosynthesis in action 2
    ... available in Spanish . Learning more ... used by U.S. Department of Agriculture (USDA) scientists to identify ... bed bugs over the last decade has caused problems in ... and even places of work. The small, blood-feeding insects are ...
    ... have found that one of the most aggressive invasive ant ... appears to have met its match in the Asian needle ... ant is successfully displacing Argentine ants in an urban environment, ... sting may be the next invasive species to see ...
    ... MDIf you have an overactive bladder or incontinence, help could be ... FASEB Journal , shows that the epithelium, a ... is able to sense how full the bladder is through the ... bladder becomes full, the cells in the epithelium stretch and become ...
    Cached Biology News:Studying bed bug actions for new management tactics 2Researchers find Asian needle ants displacing other aggressive invaders 2Got to go? Harvard scientists figure out how you know 2
    ... and PowerPac 3000 system, 220-240 V, is used ... 50 cm vertical slab gel format. The system ... is capable of separating nucleic acids with single ... (IPC) assembly (IPC and bonded inner glass plate, ...
    ... Plus overlay agarose is used for ... IPG strips in place in PROTEAN ... is incorporated to allow monitoring of ... of 0.75% agarose in 1x Tris, ...
    ... The PowerPac HV high-voltage power supply, with ... increased output of 5,000 V, 500 mA, and ... monitor gel temperature between 0 and 90 degrees ... wireless data transfer. Power cord and instructions are ...
    The stirbar is used in the buffer tank of the Trans-Blot Plus cell to maintain uniform conductivity and temperature during electrophoretic transfer. Dimensions are 3.5 x 0.5 in....
    Biology Products: